November 29, 2016 - By Louis Casey · 0 Comments
The stock of Cerulean Pharma Incorporated (NASDAQ:CERU) registered an increase of 70.75% in short interest. CERU’s total short interest was 914,900 shares in November as published by FINRA. Its up 70.75% from 535,800 shares, reported previously. With 1.87M shares average volume, it will take short sellers 1 days to cover their CERU’s short positions. The short interest to Cerulean Pharma Incorporated’s float is 5.8%. The stock closed at $0.7 during the last session. It is down 80.77% since April 26, 2016 and is downtrending. It has underperformed by 86.03% the S&P500.
Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The company has a market cap of $18.42 million. The Firm applies its Dynamic Tumor Targeting platform to develop differentiated therapies. It currently has negative earnings. The Company’s platform utilizes nanoparticle-drug conjugates , which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
Insitutional Activity: The institutional sentiment decreased to 0.56 in Q2 2016. Its down 0.17, from 0.73 in 2016Q1. The ratio dived, as 5 funds sold all Cerulean Pharma Inc shares owned while 10 reduced positions. 4 funds bought stakes while 7 increased positions. They now own 9.06 million shares or 20.36% less from 11.38 million shares in 2016Q1.
Geode Mngmt Limited Liability Corp reported 88,462 shares or 0% of all its holdings. The Pennsylvania-based Vanguard Gru has invested 0% in Cerulean Pharma Inc (NASDAQ:CERU). Bridgeway Cap Mngmt Inc has 0.01% invested in the company for 202,623 shares. Renaissance Technology Ltd Liability Corporation accumulated 64,700 shares or 0% of the stock. Principal Fincl Grp holds 0% of its portfolio in Cerulean Pharma Inc (NASDAQ:CERU) for 357,100 shares. Citadel Advsrs Ltd Com accumulated 16,000 shares or 0% of the stock. Morgan Stanley has 3,001 shares for 0% of their US portfolio. Moreover, Art Advisors has 0% invested in Cerulean Pharma Inc (NASDAQ:CERU) for 13,826 shares. Northern Tru Corporation reported 12,523 shares or 0% of all its holdings. Polaris Venture V Ltd Co has invested 7.48% of its portfolio in Cerulean Pharma Inc (NASDAQ:CERU). Deutsche Bank & Trust Ag last reported 0% of its portfolio in the stock. Sphera Funds Limited owns 450,000 shares or 0.25% of their US portfolio. Granahan Invest Mngmt Incorporated Ma reported 708,215 shares or 0.05% of all its holdings. Blackrock Inv Mgmt Ltd Liability Company holds 3,013 shares or 0% of its portfolio. Rock Springs Capital Lp has 625,000 shares for 0.1% of their US portfolio.
Out of 7 analysts covering Cerulean Pharmaceuticals (NASDAQ:CERU), 3 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 43% are positive. Cerulean Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by TH Capital given on Friday, August 28. On Tuesday, September 22 the stock rating was initiated by Barclays Capital with “Overweight”. The firm earned “Buy” rating on Wednesday, January 6 by Janney Capital. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The stock of Cerulean Pharma Inc (NASDAQ:CERU) earned “Overweight” rating by Barclays Capital on Tuesday, August 30. The stock of Cerulean Pharma Inc (NASDAQ:CERU) has “Market Perform” rating given on Thursday, August 18 by JMP Securities. Leerink Swann downgraded Cerulean Pharma Inc (NASDAQ:CERU) on Thursday, August 18 to “Market Perform” rating. Janney Capital downgraded the shares of CERU in a report on Thursday, August 18 to “Neutral” rating. The firm has “Buy” rating given on Friday, August 28 by Roth Capital. Barclays Capital maintained it with “Overweight” rating and $5 target price in Wednesday, February 24 report.
Cerulean Pharma Inc., incorporated on November 28, 2005, is a clinical-stage, oncology-focused company. The Firm applies its Dynamic Tumor Targeting platform to develop differentiated therapies. The Company’s platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. The Company’s NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. The Company’s platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company’s product pipeline consists of CRLX101 and CRLX301. The Company’s CRLX101 is a tumor targeted NDC. The Company’s CRLX301 is an NDC with docetaxel as its anti-cancer payload.
More recent Cerulean Pharma Inc (NASDAQ:CERU) news were published by: Marketwatch.com which released: “Cerulean Pharma downgraded to market perform from outperform at Leerink Partners” on April 17, 2014. Also Quotes.Wsj.com published the news titled: “News Cerulean Pharma Inc.CERU” on April 06, 2014. Streetinsider.com‘s news article titled: “Cerulean Pharma (CERU) Says CRLX101 Combo Phase 2 Missed Primary Endpoint” with publication date: August 17, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey